FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/09/073966 [Registered on: 17/09/2024] Trial Registered Prospectively
Last Modified On: 17/09/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Biological 
Study Design  Single Arm Study 
Public Title of Study   A study to know the predictability of treatment outcomes with OCT scan of the eye in patients undergoing injections of a class of drug known as anti-VEGFs for diabetic macular edema 
Scientific Title of Study   The Role Of OCT-Based Biomarkers For Predicting Treatment Response In Eyes With Centre Involving Diabetic Macular Oedema Treated With Anti-VEGF Injections 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Neeraja N Varma 
Designation  DNB Resident 
Affiliation  Nethradhama Super Speciality Eye Hospital 
Address  Nethradhama Super Speciality Eye Hospital, 256/14, Kanakpura main road, opp ICICI bank, jayanagar, 7th block.
Room 5, Ground floor, General OPD, OPD Block
Bangalore
KARNATAKA
560070
India 
Phone  9846422040  
Fax    
Email  neeraja.n.varma@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Mamatha N 
Designation  Senior consultant, department of vitreoretina  
Affiliation  Nethradhama Super Speciality Eye Hospital 
Address  Nethradhama Super Speciality Eye Hospital, 256/14, Kanakapura Rd, 7th Block, Jayanagar, Bengaluru, Karnataka 560070
Room 1, Department of vitreoretina, 1st floor, Speciality block
Bangalore
KARNATAKA
560070
India 
Phone  7795245633  
Fax    
Email  mamtha.doc@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Mamatha N 
Designation  Senior consultant, department of vitreoretina 
Affiliation  Nethradhama Super Speciality Eye Hospital 
Address  Nethradhama Super Speciality Eye Hospital, 256/14, Kanakapura Rd, 7th Block, Jayanagar, Bengaluru, Karnataka 560070
Room 1, Department of vitreoretina, 1st floor, Speciality block
Bangalore
KARNATAKA
560070
India 
Phone  7795245633  
Fax    
Email  mamtha.doc@gmail.com  
 
Source of Monetary or Material Support  
Nethradhama Super Speciality Eye Hospital, 256/14, Kanakapura Rd, 7th Block, Jayanagar, Bengaluru, Karnataka, India, 560070 
 
Primary Sponsor  
Name  Nethradhama Superspeciality Eye Hospital 
Address  256/14, Kanakpura Main Road, 7th Block, Jayanagar, Bangalore, 560070 
Type of Sponsor  Other [SELF] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Neeraja N Varma  Nethradhama Superspeciality Eye Hospital  Nethradhama superspecialty hospital, SPC block, 1st floor, department of retina, 256/14, Kanakpura Main Road, 7th Block, Jayanagar, Bangalore 560070
Bangalore
KARNATAKA 
9846422040

neeraja.n.varma@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
The Ethics Committee Nethradhama Super Speciality Eye Hospitall  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E113||Type 2 diabetes mellitus with ophthalmic complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Anti-VEGF Injection  The study aims to investigate the association between SD-OCT Biomarkers and the treatment response among Diabetic Macular Oedema eyes treated with intravitreal Anti-VEGF Injection. Dose and frequency: as required by patient Route: intravitreal Duration within 18 Months of first dose  
Comparator Agent  Non applicable  Non applicable 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Pateints with either type 1 or type 2 Diabetes Mellitus aged 18 years or older, who have consented for the study.
Centre-Involving Diabetic Macular Oedema (DMO), defined by sub-foveal involvement of abnormal intraretinal and/or subretinal fluid with concurrent thickening affecting the 1mm diameter of CST 
 
ExclusionCriteria 
Details  1. Pre-existing retinal or macular disease other than DR or DMO
2. SD-OCT images with porr quality
3. Pre-existing ocular diseases such as cataract, glaucoma, pathological myopia and uveitis
4. Any cataract surgery done in past 3 months
5. Prior vitreoretinal surgery or intravitreal anti-VEGF injections
6. Patients who have undergone any supplementary macular laser and / or intravitreal steroid implants  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
1. Morphology of DMO
2. Vitreomacular relationship
3. Presence of DRIL
4. Presence and number of hyperreflective retinal foci
5. Presence of hyper-reflectivity within intra-retinal cyst
6. Visibility and continuity of ELM or EZ 
Taken before injection and at 1 month post injection 
 
Secondary Outcome  
Outcome  TimePoints 
If there is any improvement in visual acuity of the patient   Taken at 3 months & 6 months post injection 
 
Target Sample Size   Total Sample Size="44"
Sample Size from India="44" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   30/09/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
AIM
To investigate the associations between SD-OCT biomarkers and the treatment response among DMO eyes
treated with intravitreal anti-VEGF injection
OBJECTIVES
1. To assess the correlation with baseline SD-OCT biomarkers and baseline VA
2. To assess correlation between baseline SD-OCT biomarkers and subsequent VA after anti-VEGF
treatment
3. To compare SD-OCT biomarkers in DMO patients before and after anti-VEGF injection

MATERIALS AND METHODS

STUDY DESIGN
Longitudinal prospective cohort study

STUDY POPULATION:
Inclusion criteria:
1. Patients with either type 1 or type 2 DM aged 18 years or older, who have consented for the study
2. CI-DMO, defined by SD-OCT foveal involvement of abnormal intraretinal and/or subretinal fluid
with concurrent thickening affecting the 1mm diameter of CST
Exclusion criteria:
1. Pre-existing retinal or macular disease other than DR or DMO
2. SD-OCT images with poor quality that was insufficient for assessment
3. Pre-existing ocular diseases such as cataract, glaucoma, pathological myopia and uveitis
4. Any cataract surgery done in past 3 months
5. Prior vitreoretinal surgery or intravitreal anti-VEGF injections
6. Patients who have undergone any supplementary macular laser and/or intravitreal steroid implants

STUDY DURATION
18 months (one and a half years)

STUDY SETTING:
Retina clinic at Nethradhama Superspeciality Eye Hospital, Jayanagar, Bengaluru- 560070. The hospital
is equipped with Spectral domain OPTICAL COHERENCE TOMOGRAPHY, "HEIDELBERG HRAI
SPECTRALIS"

SAMPLE SIZE
Sample size calculation was based on the principal of “Inference for a mean, comparing a mean to know a
value.’ To calculate the sample size, a reference study was used. The mean baseline best corrected visual
acuity was 0.62 Log MAR units and after the last anti-VEGF injection was 0.49 Log MAR units, respectively.
The standard deviation was 0.3. Considering 80% power (alpha = 0.05), and a precision error of 5% to detect
difference of 20% or more in BCVA, the estimated sample size was calculated to be 44.

PROCEDURE:
All treatment naïve patients with diabetes with CI-DMO, who have been indicated intravitreal anti-VEGF
injections will be recruited for this study. After explaining the nature and purpose of the study, an informed
consent will be taken. Their baseline demographics such as age, gender, duration of DM, HbA1c levels and
other associated co-morbidities will be taken. Baseline ophthalmic examination including VA measured with
Snellen’s chart and converted to Logarithm of the Minimum Angle of Resolution (logMAR) scale, severity
of DR and DMO status will be recorded. VA at baseline, `, 3 and 6 months will be recorded. The number
and type of anti-VEGF injections will also be noted. OCT will be done prior to anti-VEGF therapy and at 1
month, 3 months and 6 months follow-up. The OCT will be assessed based on the below mentioned
parameters.

OCT Image Analysis
All OCT images will be analysed by 2 retina specialists.
Quantitative measurement, namely the CST was provided by the in-built Spectralis software using the volume
scan, consisting of 25 lines horizontal raster scans covering 20°×20°, centred on fovea.
Qualitative analysis of the OCT images was graded based on the scan passing through the fovea centre and
the 3 B-scans immediately superior and inferior to the fovea. The following qualitative parameters will be
analysed
1. Morphology of DMO.
2. Vitreomacular relationship.
3. The presence of DRIL.
4. The presence and number of hyper-reflective retinal foci (HRF).
5. The presence of Hyper-reflectivity within the intra-retinal cyst.
6. The visibility and continuity of ELM and EZ.
Morphology of DMO was classified based on OCT findings into (1) CMO, defined as presence of intraretinal
cystoid spaces; (2) Diffuse retinal thickening (DRT), defined as diffuse sponge like thickening of retina and
(3) Serous retinal detachment (SRD), defined as the presence of subretinal fluid. Patients may have one or
more of these features concurrently.

Vitreomacular relationship will be classified according to the International Vitreomacular Traction Study
Group classification28 into (1) no visible vitreoretinal adhesion; (2) incomplete vitreous detachment; (3)
complete posterior vitreous detachment; (4) vitreomacular traction; and (5) epiretinal membrane.
DRIL is defined as the inability to segment the boundaries of the OPL, INL and the GCL-IPL complex on the
central 1 mm zone of horizontal scan centred on fovea. It was graded as either absent or present23.
Presence of hyper-reflectivity within the intra-retinal cyst is described as any hyper-reflectivity seen within
the cystic spaces. It’ll be indicated as present/absent.
Hyper-reflective foci (HRF) is defined as circumscribed dots with similar reflectivity in the retinal nerve fibre
layer, absence of back-shadowing and <30μm diameter. HRF is defined as hyper-reflective foci between
internal limiting membrane and RPE. HRF is not to be confused with hard exudates which arises from lipid
exudation. The number of hyper-reflective foci will be counted manually based on the 1mm zone of the
horizontal scan centred on fovea21. HRF will be graded into three groups: no hyper-reflective foci, 1–10 hyperreflective
foci and >10 hyper-reflective foci, respectively.
The visibility and continuity of ELM and EZ will be graded within the central 1mm wide area of the horizontal
B-scan centred on fovea centre. ELM and EZ are defined as the first three hyper-reflective bands of the four
outer- most layers on SD-OCT, with the third band being COST and the fourth hyper-reflective band being
RPE. Each layer will classified into intact, disrupted (partially visible and discernible) and absent (not
discernible at all). The ELM and EZ will be interpreted as a unit because in the presence of subretinal fluid
where EZ cannot be identified, the integrity of ELM would be graded instead21.

STATISTICAL ANALYSIS
Data will be entered in MS excel and analysed using SPSS software. Qualitative data will be presented in the
form of Proportions and pie diagrams, bar charts will be used to represent graphically. All categorical variables
will be summarised using frequency and percentage. Continuous variables will be summarised using mean
and standard deviation if data follows normality, else, median and IQR will be used. Student’s t test will be
the test of significance for quantitative data and chi-square test will be the test of significance for qualitative
data. p value <0.05 will be considered as statistically significant.
 
Close